GSK plc (GSK) Stock
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
GSK plc (GSK) stock trades at $51.58 with a market capitalization of $103.73B. The stock is valued at a price-to-earnings (P/E) ratio of 9.28, price-to-book of 6.35, price-to-sales of 2.34. Over the past 52 weeks the stock has ranged between $35.45 and $61.70, and currently trades 16.4% below its 52-week high. It pays a dividend yielding 3.49%.
On profitability, GSK plc generates a return on equity (ROE) of 34.96% — well above the market average, a sign of a high-quality business, return on capital employed of 52.13%, an operating margin of 22.34%, a net profit margin of 17.78%.
In its most recent fiscal year, GSK plc reported annual revenue of $32.7B, net profit of $5.7B, revenue has compounded at 6.0% a year over the last five years, profit at -0.1% a year.
The balance sheet shows a debt-to-equity ratio of 1.07, a current ratio of 0.82, total assets of $61.0B, $3.4B in cash and equivalents.
GSK has an average daily trading volume of 4,050,477 shares, a beta of 0.29 (less volatile than the overall market).
Official website: www.gsk.com